Columbus, United States
Forge Biologics, established in 2020 and headquartered in the United States, is part of Ajinomoto Bio-Pharma Services and operates within the Biotechnology and Health Care sectors. This specialized company serves as a gene therapy development engine, strategically collaborating with innovators in the field, including scientists, physicians, biotech/pharma companies, and patient groups.
With a commitment to a patients-first philosophy, Forge Biologics plays a critical role in transforming gene therapy ideas into clinical realities. The company supplies expertise in gene therapy manufacturing and therapeutics development, accelerating the journey of ground-breaking medicines from concept to treatment availability.
Financially robust, Forge Biologics secured a $90.00M Series C investment on September 12, 2022, supported by investors such as Drive Capital and Aisling Capital. This injection of funds not only reinforces their strategic endeavors but also solidifies their role as a pivotal force in the accelerating gene therapy landscape.
